Literature DB >> 8046458

Voltage-sensitive calcium channels in spinal nociceptive processing: blockade of N- and P-type channels inhibits formalin-induced nociception.

A B Malmberg1, T L Yaksh.   

Abstract

The role of spinal voltage-sensitive calcium channels (VSCC) in a behavioral model of prolonged nociception was examined in rats. Blockade of VSCC by the trivalent cations neodymium (NdCl3) and lanthanum (LaCl3) resulted in a dose-dependent suppression of both phases of the response to formalin. omega-Conopeptides, which selectively block N-type VSCC, also produced a dose-dependent inhibition of both the initial behavior [phase 1; ED50 (nmol): SNX-111 (0.003) > SNX-185 (0.010) > SNX-239 (0.16) >> SNX-159 (> 0.26); SNX-199 (> 0.30)] and the facilitated response [phase 2; ED50 (nmol): SNX-111 (0.003) > SNX-185 (0.009) > SNX-239 (0.020) > SNX-159 (0.120) = SNX-199 (0.230)]. In contrast, SNX-231 (0.24 nmol), which is selective for a non-L/non-N site and also the L-type VSCC blockers nifedipine (24 nmol), nimodipine (29 nmol), verapamil (200 nmol), and diltiazem (220 nmol), had minimal effects on either phase of the formalin test at the highest dose examined. The P-type channel blocker omega-agatoxin IVA produced a 40% inhibition of phase 1 at the highest dose and phase 2 was suppressed in a dose-dependent fashion (ED50, 0.001 nmol). The response latency to a high-threshold thermal stimulus (the 52.5 degrees C hot plate) was moderately (20%) increased by NdCl3 (0.30 nmol) and SNX-111 (0.008 nmol), but not verapamil (200 nmol) and omega-agatoxin IVA (0.006 nmol). High doses of the N-type VSCC produced characteristic shaking behavior, serpentine-like tail movements, and impaired coordination. However, at antinociceptive doses there was no significant motor effect, though three of the N-type antagonists produced some tail movements. These studies demonstrate that VSCC of the N- and P-type, but not L-type, are involved in facilitated nociceptive processing at the spinal level.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8046458      PMCID: PMC6577170     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  55 in total

Review 1.  Antidepressants as analgesics: an overview of central and peripheral mechanisms of action.

Authors:  J Sawynok; M J Esser; A R Reid
Journal:  J Psychiatry Neurosci       Date:  2001-01       Impact factor: 6.186

2.  Modulation of formalin-evoked hyperalgesia by intrathecal N-type Ca channel and protein kinase C inhibitor in the rat.

Authors:  O Nakanishi; T Ishikawa; Y Imamura
Journal:  Cell Mol Neurobiol       Date:  1999-04       Impact factor: 5.046

3.  Suppression of inflammatory and neuropathic pain symptoms in mice lacking the N-type Ca2+ channel.

Authors:  H Saegusa; T Kurihara; S Zong; A Kazuno ; Y Matsuda; T Nonaka; W Han; H Toriyama; T Tanabe
Journal:  EMBO J       Date:  2001-05-15       Impact factor: 11.598

Review 4.  Targeting voltage-gated calcium channels: developments in peptide and small-molecule inhibitors for the treatment of neuropathic pain.

Authors:  S Vink; P F Alewood
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

5.  Differential effects of voltage-gated calcium channel blockers on calcium channel alpha-2-delta-1 subunit protein-mediated nociception.

Authors:  E Chang; X Chen; M Kim; N Gong; S Bhatia; Z D Luo
Journal:  Eur J Pain       Date:  2014-08-27       Impact factor: 3.931

6.  Painful peripheral nerve injury decreases calcium current in axotomized sensory neurons.

Authors:  J Bruce McCallum; Wai-Meng Kwok; Damir Sapunar; Andreas Fuchs; Quinn H Hogan
Journal:  Anesthesiology       Date:  2006-07       Impact factor: 7.892

Review 7.  Role of decreased sensory neuron membrane calcium currents in the genesis of neuropathic pain.

Authors:  Quinn H Hogan
Journal:  Croat Med J       Date:  2007-02       Impact factor: 1.351

Review 8.  Targeting chronic and neuropathic pain: the N-type calcium channel comes of age.

Authors:  Terrance P Snutch
Journal:  NeuroRx       Date:  2005-10

Review 9.  Pregabalin in the treatment of chronic pain: an overview.

Authors:  S Chiechio; M Zammataro; F Caraci; L Rampello; A Copani; A F Sabato; F Nicoletti
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

10.  Group I metabotropic glutamate receptor NMDA receptor coupling and signaling cascade mediate spinal dorsal horn NMDA receptor 2B tyrosine phosphorylation associated with inflammatory hyperalgesia.

Authors:  Wei Guo; Feng Wei; Shiping Zou; Meredith T Robbins; Shinichi Sugiyo; Tetsuya Ikeda; Jian-Cheng Tu; Paul F Worley; Ronald Dubner; Ke Ren
Journal:  J Neurosci       Date:  2004-10-13       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.